NAFTIFINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAFTIFINE HYDROCHLORIDE (NAFTIFINE HYDROCHLORIDE).
Naftifine hydrochloride is an allylamine antifungal that inhibits squalene epoxidase, an enzyme involved in ergosterol synthesis, leading to accumulation of squalene and disruption of fungal cell membrane function.
| Metabolism | Systemic absorption after topical application is minimal (<6%). Naftifine undergoes hepatic metabolism via oxidation and N-dealkylation, primarily by CYP3A4. |
| Excretion | Following topical application, systemic absorption is minimal (<6%). Absorbed drug is primarily eliminated via hepatic metabolism and renal excretion. Approximately 40-60% of absorbed dose is excreted in urine as metabolites and unchanged drug, with the remainder eliminated in feces via biliary excretion. |
| Half-life | Terminal elimination half-life is approximately 2-3 days. This long half-life supports once-daily or twice-weekly dosing regimens for dermatophyte infections. |
| Protein binding | Naftifine hydrochloride is >99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Following systemic absorption, the apparent volume of distribution is approximately 4-6 L/kg, indicating extensive tissue distribution, particularly to skin and adipose tissue. |
| Bioavailability | Topical: Systemic bioavailability is <6% of the applied dose due to minimal percutaneous absorption. After oral administration (not clinically used), bioavailability would be extensive but is not relevant for the approved topical route. |
| Onset of Action | Topical: Clinical improvement (reduction in erythema, scaling, pruritus) typically begins within 1-2 weeks of once-daily application. Complete mycological cure may require 4-8 weeks depending on infection site. |
| Duration of Action | Topical: The drug persists in the stratum corneum for up to 72 hours after a single application, allowing for once-daily or even twice-weekly dosing. Clinical cure rates at 4 weeks post-treatment are high. |
| Molecular Weight | 287.35 |
Apply a thin layer of 1% cream or gel to affected area once daily for 4 weeks for tinea pedis, 2 weeks for tinea cruris and tinea corporis. For tinea versicolor, apply once daily for 2 weeks.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. Systemic absorption is minimal (<6%), and no studies indicate need for modification. |
| Liver impairment | No dose adjustment required for hepatic impairment. Systemic absorption is minimal (<6%), and no studies indicate need for modification. |
| Pediatric use | Safety and efficacy in pediatric patients below 12 years have not been established. For children ≥12 years, use same dosing as adults. |
| Geriatric use | No specific dose adjustment required. Use same dosing as for younger adults; minimal systemic absorption reduces risk of systemic effects. |
| 1st trimester | Limited human data; animal studies show no evidence of harm. Use only if clearly needed. |
| 2nd trimester | Limited human data; animal studies show no evidence of harm. Use only if clearly needed. |
| 3rd trimester | Limited human data; animal studies show no evidence of harm. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for NAFTIFINE HYDROCHLORIDE (NAFTIFINE HYDROCHLORIDE).
| Placental transfer | Unknown; molecular weight suggests potential for transfer. |
| Breastfeeding | Excretion in human milk unknown. Use caution; avoid application to breast area. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to naftifine or any component of the formulation
| Precautions | For external use only; avoid contact with eyes, nose, mouth, and other mucous membranes., May cause local irritation, burning, stinging, or allergic contact dermatitis., Discontinue if irritation or sensitivity develops. |
| Food/Dietary | No known food interactions. Naftifine is applied topically and systemic absorption is minimal. No dietary restrictions necessary. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies have shown no evidence of teratogenicity or fetotoxicity at doses up to 10 times the human topical dose. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond routine prenatal care. Assess for local adverse reactions or signs of systemic toxicity, though rare. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies have not shown impairment of fertility at topical doses up to 10 times the human dose. |
| Naftifine hydrochloride is an allylamine antifungal that inhibits squalene epoxidase, leading to accumulation of squalene and fungal cell death. It has both fungicidal and fungistatic activity against dermatophytes. Unlike azoles, it does not inhibit cytochrome P450 14α-demethylase, thus no significant drug interactions via CYP3A4. Apply once daily for tinea pedis, tinea cruris, and tinea corporis. Clinical response may be seen within 1-4 weeks. For interdigital tinea pedis, cure rates at 2 weeks post-treatment are superior to clotrimazole. Avoid occlusive dressings unless directed. |
| Patient Advice | Apply a thin layer to the affected area and surrounding skin once daily, or as directed by your doctor. · Wash hands before and after application, unless treating the hands. · Do not cover the treated area with bandages or airtight dressings unless instructed otherwise. · Use the medication for the full prescribed duration, even if symptoms improve early, to prevent recurrence. · Avoid contact with eyes, nose, mouth, or broken skin. If accidental contact occurs, rinse thoroughly with water. · Inform your doctor if the condition worsens or does not improve after 4 weeks of treatment. |